eMedicine Specialties > Emergency Medicine > Toxicology
Plant Poisoning, Glycosides - Coumarin
Updated: Aug 14, 2008
Introduction
Background
Toxicity from coumarins was first noted in animals. Livestock were difficult to feed on North American prairies until the introduction of melilots, or sweet clovers (ie, Melilotus alba, Melilotus officinalis), from Europe in the early 1900s.
In 1924, Schofield noted cattle in Alberta that were fed moldy spoiled sweet clover hay were dying from a previously undescribed hemorrhagic disorder; properly cured hay appeared harmless. Bishydroxycoumarin, the active ingredient responsible for this hemorrhagic disorder, was discovered in 1939 by Campbell and Link.
Bishydroxycoumarin is formed when fungi in moldy sweet clover oxidize coumarin to 4-hydroxycoumarin, an anticoagulant. In 1940, bishydroxycoumarin was synthesized and used clinically 1 year later as an oral anticoagulant under the American trade name dicumarol.
Coumarin-derivatives possessing a 4-hydroxy group with a carbon at the 3 position of the coumarin-base structure possess anticoagulant activity and are referred to as hydroxycoumarins, which are not present in coumarin itself.
Warfarin (name derived from Wisconsin Alumni Research Foundation and Coumarin) was synthesized and used as a rodenticide for nearly a decade prior to its 1954 introduction into clinical medicine.
Today, the 4-hydroxy coumarins are primarily used as anticoagulants and rodenticides. Second-generation rodenticides (long-acting anticoagulants, such as brodifacoum) are characterized by their clinical effects and very long half-lives.
Coumarin-derived products may be synthesized or obtained from tonka seeds (Dipteryx odorata, Dipteryx oppositifolia). Oral anticoagulants are divided into two groups, hydroxycoumarins (including warfarin) and indanediones.
This chapter focuses on hydroxycoumarins and their anticoagulant effects.
Pathophysiology
Vitamin K is a cofactor required for the postribosomal synthesis of active coagulation factors II, VII, IX, and X, as well as proteins S and C (important modulators of coagulation). Synthesis of these factors involves the carboxylation of specific glutamic acid residues in the liver, a step dependent on reduced vitamin K (vitamin K quinol). In this carboxylation reaction, vitamin K is oxidized to vitamin K 2, 3-epoxide. The 4-hydroxycoumarins block vitamin K 2, 3-epoxide reductase, which is needed for the reduction of vitamin K epoxide back to its active form. Dysfunctional coagulation factors are produced in the absence of reduced vitamin K. Half-lives of clotting factors are as follows:
- Factor II - 60 hours
- Factor VII - 4-6 hours
- Factor IX - 24 hours
- Factor X - 48 -72 hours
The bioavailability of warfarin is nearly complete when administered orally, intramuscularly, intravenously, or rectally. Therefore, orally ingested warfarin is completely absorbed and peak plasma concentrations occur about 3 hours postadministration. Ninety-nine percent is bound to plasma proteins, principally albumin, and distributes into a volume equivalent to the albumin space. Depletion of circulating coagulation factors must occur before any effects are evident. Factor VII has the shortest half-life; factor II has the longest. Clinical effects of a single massive dose of warfarin may begin to be apparent by 24 hours and are maximal by 36-48 hours. The patient may be hypercoagulable for a period of several hours after warfarin ingestion, prior to inhibition of factor production. Duration of action may be as long as 5 days.
Warfarin is metabolized extensively by hepatic microsomal enzymes and undergoes enterohepatic recirculation. Warfarin and its metabolites are excreted in urine and feces.
Long-acting anticoagulants, rodenticides, or superwarfarins (eg, difenacoum, brodifacoum) are 4-hydroxycoumarin derivatives; they are highly lipid-soluble and concentrate in the liver. Superwarfarins have a much longer duration of action than traditional warfarins. After intentional overingestion of superwarfarins, patients may be anticoagulated for weeks to months.
Numerous drug interactions with warfarin exist, both accelerating and inhibiting its metabolism. Lack of attention to possible interactions is a common cause of iatrogenic toxicity.
Drugs that potentiate anticoagulation are allopurinol, amiodarone, anabolic steroids, cephalosporins, cimetidine, cyclic antidepressants, erythromycin, ethanol, fluconazole, ketoconazole, metronidazole, nonsteroidal anti-inflammatory drugs (NSAIDs), omeprazole, sulfonylureas, thyroxine, and trimethoprim-sulfamethoxazole.
Drugs that antagonize anticoagulation are antacids, antihistamines, barbiturates, carbamazepine, corticosteroids, griseofulvin, oral contraceptives, phenytoin, and rifampin.
Frequency
United States
Intentional ingestion of warfarin-containing products is rare; however, excessive anticoagulation and bleeding are not uncommon in patients taking warfarin therapeutically. In 1998, 1658 exposures to warfarin were reported to the American Association of Poison Control Centers (AAPCC). These centers cover approximately 95% of the US population, although reports to the AAPCC underestimate true incidence of exposures and poisonings. Of these exposures, 235 were intentional. Of all warfarin exposures, 47 major outcomes (life-threatening event or resultant disability) and 2 deaths were reported. In the same report, 17,724 exposures to anticoagulant rodenticides were documented; 58 were intentional. A total of 28 major outcomes and 1 death were reported.
Mortality/Morbidity
Bleeding indicates major toxicity of 4-hydroxycoumarins.
- Mucocutaneous, genitourinary, and GI are the most frequent sites of bleeding.
- Serious bleeding includes massive hemorrhage with shock, intracranial bleeding, stroke, and pericardial tamponade.
- Upper airway compromise due to an expanding hematoma also may occur.
Age
- Intentional and chronic ingestions are more common in adolescents and adults than children. Munchausen syndrome or Munchausen syndrome by proxy may present as surreptitious ingestion or administration of one of these compounds by a caretaker.
- Single accidental ingestions are the most common exposures in children younger than 6 years. Such exposures to warfarin or brodifacoum rarely result in clinical toxicity.
Clinical
History
- Elicit a history of exposure to medicinal hydroxycoumarins or rodenticides.
- History may be difficult to obtain from patients who have ingested hydroxycoumarin products surreptitiously or with suicidal intent.
- Ask the following questions to ascertain specific history:
- Was ingestion a pharmaceutical or a long-acting rodenticide preparation?
- Was ingestion intentional or unintentional? (Single unintentional ingestions of warfarin and warfarin-containing rodenticides usually are harmless; however, intentional and large unintentional ingestions of pharmaceutical-grade anticoagulants or rodenticides can produce life-threatening bleeding.)
- How much was ingested?
- When did the ingestion occur?
- Was the ingestion a single acute ingestion or a chronic ingestion?
Physical
Bleeding diathesis does not occur until 24 hours postingestion. Continued re-evaluation for signs of coagulopathy is necessary.
Complications of excessive anticoagulation may occur. Initially, assessment of hemodynamic status and neurologic status are most important.
- Excessive ecchymosis and skin necrosis
- Purpura
- Subconjunctival hemorrhage
- Bleeding gums
- Epistaxis
- Menorrhagia
- Gross hematuria
- Hematomas
- Compartment syndromes
- Immediately life-threatening hemorrhage
- Massive GI bleeding (eg, hematemesis, melena)
- Intracranial hemorrhage
- Upper airway compromise due to expanding hematoma
Causes
Warfarin anticoagulants and the anticoagulant rodenticides (Human toxicity from ingestion of plants and herbal medications is extremely rare.)
More on Plant Poisoning, Glycosides - Coumarin |
 Overview: Plant Poisoning, Glycosides - Coumarin |
| Differential Diagnoses & Workup: Plant Poisoning, Glycosides - Coumarin |
| Treatment & Medication: Plant Poisoning, Glycosides - Coumarin |
| Follow-up: Plant Poisoning, Glycosides - Coumarin |
| References |
| Next Page » |
References
Berry RG, Morrison JA, Watts JW, et al. Surreptitious superwarfarin ingestion with brodifacoum. South Med J. Jan 2000;93(1):74-5. [Medline].
Chen IS, Chang CT, Sheen WS. Coumarins and antiplatelet aggregation constituents from Formosan Peucedanum japonicum. Phytochemistry. Feb 1996;41(2):525-30. [Medline].
Collins Abrams A. Clinical Drug Therapy. 5th ed. Lippincott; 1997.
Hahn A, Oertreich S, Barkin R. Mosby's Pharmacology in Nursing. 16th ed. 1986.
Hardman JG, et al. Goodman and Gilman's the Pharmacological Basis of Therapeutics. 9th ed. Macmillan; 1996.
Hoult JR, Paya M. Pharmacological and biochemical actions of simple coumarins: natural products with therapeutic potential. Gen Pharmacol. Jun 1996;27(4):713-22. [Medline].
Klassen C, Amdur M, Doull J. Casarett and Doull's Toxicology. 3rd ed. Macmillan; 1986.
Kruse JA, Carlson RW. Fatal rodenticide poisoning with brodifacoum. Ann Emerg Med. Mar 1992;21(3):331-6. [Medline].
La Rosa FG, Clarke SH, Lefkowitz JB. Brodifacoum intoxication with marijuana smoking. Arch Pathol Lab Med. Jan 1997;121(1):67-9. [Medline].
Martin EW, et al. Remington's Pharmaceutical Sciences. 13th ed. Mack Publishing Co; 1965.
Ministry of Agriculture, Fisheries and Food (MAFF). Food Surveillance Information Sheets. Survey of biologically active principles in mint products and herbal teas. November 1996. Accessed December 10, 2004. [Full Text].
Morgan BW, Tomaszewski C, Rotker I. Spontaneous hemoperitoneum from brodifacoum overdose. Am J Emerg Med. Nov 1996;14(7):656-9. [Medline].
Mullins ME, Brands CL, Daya MR. Unintentional pediatric superwarfarin exposures: do we really need a prothrombin time?. Pediatrics. Feb 2000;105(2):402-4. [Medline].
Olsen KR. Poisoning and Drug Overdose. San Francisco Bay Area Regional Poison Control Center. Norwalk, Conn: Appleton and Lange; 1990.
Pengsuparp T, Serit M, Hughes SH, et al. Specific inhibition of human immunodeficiency virus type 1 reverse transcriptase mediated by soulattrolide, a coumarin isolated from the latex of calophyllum teysmannii. J Nat Prod. Sep 1996;59(9):839-42. [Medline].
Renowden S, Westmoreland D, White JP, Routledge PA. Oral cholestyramine increases elimination of warfarin after overdose. Br Med J (Clin Res Ed). Aug 24 1985;291(6494):513-4. [Medline].
Rosen P. Emergency Medicine Concepts and Clinical Practice. 4th ed. Mosby; 1997.
Rund D, Barkin R, Rosen P. Essentials of Emergency Medicine. 2nd ed. Mosby Lifeline; 1996.
Tintinalli J, Krome R, Ruiz E. Emergency Medicine; A Comprehensive Study Guide. 4th ed. McGraw-Hill; 1995.
Travis SF, Warfield W, Greenbaum BH, et al. Spontaneous hemorrhage associated with accidental brodifacoum poisoning in a child. J Pediatr. Jun 1993;122(6):982-4. [Medline].
Whyte AC, Gloer JB, Scott JA, Malloch D. Cercophorins A-C: novel antifungal and cytotoxic metabolites from the coprophilous fungus Cercophora areolata. J Nat Prod. Aug 1996;59(8):765-9. [Medline].
Williams CA, Goldstone F, Greenham J. Flavonoids, cinnamic acids and coumarins from the different tissues and medicinal preparations of Taraxacum officinale. Phytochemistry. May 1996;42(1):121-7. [Medline].
Further Reading
Keywords
plant glycosides, glycosides coumarin, warfarin, hydroxycoumarins, coumarin derivatives, coumarin toxicity, plant poisonings, glycoside toxicity, glycoside poisoning, coumarin exposure, coumarin anticoagulants, coumarin rodenticides
